Financings in Brief: St. Jude Medical
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical: "Dutch auction" self-tender offer commences Feb. 12 for the repurchase of up to 8 mil. shares of stock. Under the terms of the offer, shareholders have an opportunity to specify prices between $32 and $39 per share at which they are willing to tender their shares. Upon receipt of the tenders, St. Jude will offer a price at or below the requested purchase prices that will enable it to purchase up to 8 mil. shares. The issue closed at $34.6875 on Feb. 11. Approximately 91.9 mil. shares are outstanding. Commenting on the offer that expires March 12, St. Jude Chairman and CEO Ronald Matricaria says: "The board of directors believes this offer is an attractive use of the company's financial resources and that the use of cash and borrowing to fund the offer will result in a more efficient capital structure for St. Jude." Credit Suisse First Boston is dealer manager for the offer...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.